LKFT

Lakefront Biotherapeutics - ADR

32.16

USD

-0.17

-0.52%

Oct 30, 14:45 UTC -4

Open

Lakefront Biotherapeutics - ADR (LKFT) Earnings

LKFT Earnings Reports

Positive Surprise Ratio

LKFT beat 3 of 3 last estimates.

100%

Next Report

Date of Next Report

Nov 12, 2026

Estimate for Q3 26 (Revenue/ EPS)

$76.33M

-$0.43

Implied change from Q2 26 (Revenue/ EPS)

+530.29%

-1533.33%

Implied change from Q3 25 (Revenue/ EPS)

-85.99%

Lakefront Biotherapeutics - ADR earnings per share and revenue

On Aug 10, 2026, LKFT reported earnings of 0.03 USD per share (EPS) for Q2 26, beating the estimate of -0.43 USD, resulting in a 106.84% surprise. Revenue reached 12.11 million, compared to an expected 76.33 million, with a -84.13% difference. The market reacted with a +6.76% price change (close before vs. close after earnings).

Looking ahead to Q3 26, -- analysts forecast an EPS of -0.43 USD, with revenue projected to reach 76.33 million USD, implying an decrease of -1533.33% EPS, and increase of 530.29% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

PTC Therapeutics, Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$0.34

Actual

$0.61

Surprise

+75.59%

Bristol-Myers Squibb Co.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.20

Actual

$1.35

Surprise

+11.66%

Regeneron Pharmaceuticals Inc

Report Date

Oct 30, 2026 For Q3 26

Estimate

$16.47

Actual

$20.07

Surprise

+21.79%

Illumina Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.38

Actual

$1.44

Surprise

+4.18%

Insmed, Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$0.38

Actual

-$0.46

Surprise

-19.82%

Incyte Genomics Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$3.92

Actual

-$3.60

Surprise

+8.33%

Alnylam Pharmaceuticals, Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.65

Actual

$16.26

Surprise

+885.34%

Exelixis Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$0.81

Actual

$0.94

Surprise

+15.64%

Kymera Therapeutics, Inc. Common Stock

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$1.29

Actual

-$1.32

Surprise

-2.17%

NovoCure Limited Ordinary Shares

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$0.24

Actual

-$0.09

Surprise

+63.88%

FAQ

What were Lakefront Biotherapeutics - ADR's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Lakefront Biotherapeutics - ADR reported EPS of $0.03, beating estimates by 106.84%, and revenue of $12.11M, -84.13% below expectations.

How did the market react to Lakefront Biotherapeutics - ADR's Q2 2026 earnings?

The stock price moved up 6.76%, changed from $26.91 before the earnings release to $28.73 the day after.

When is Lakefront Biotherapeutics - ADR expected to report next?

The next earning report is scheduled for Nov 12, 2026.

What are the forecasts for Lakefront Biotherapeutics - ADR's next earnings report?

Based on -- analysts, Lakefront Biotherapeutics - ADR is expected to report EPS of -$0.43 and revenue of $76.33M for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.